Ioannis Politikos

Excited to chair the “There’s a Donor for Everyone” session at #CBC2024, thanks to @CordBloodAssn. Honored to share the stage with @MGooptu and @ipolitikos. Big strides in HCT access, but there’s still more to do! @nmdp_org @SylvesterCancer

Wonderful sharing the stage with these rising stars! @amjimenezmd @ipolitikos

Llampacas at #Tandem24 @ASTCT @DrMiguelPerales @ipolitikos

Fascinating talk @DrBetofMDPhD!

Thank you @BMDACCstemcell and @NeeshR0 for an outstanding Symposium and for the invitation to present our data! #sctsymposiumBMDACC #bmtsm

@AndrlovaHana Congrats Hana!

Excited to share that my journey in the US and NYC continues, I matched to Mount Sinai internal medicine residency!

First #GVHDday at #Tandem23 @GrayVPharmD @ipolitikos @ASTCT @CIBMTR #GVHDconnect4hope

@AaronGoodman33 Curability of AML without transplant very low (especially non CBF AML) ashpublications.org/bloodadvances/…

@ASTCT @BeTheMatch @AndrewRezvani @fmilano976 @DocBrunstein @NMDP @CIBMTR Finally, as there is no well established calcineurin inhibitor(CNI)-free GVHD ppx regimen for #cordblood transplantion, patients with impaired renal function that are unlikely to tolerate CNI may not be ideal candidates.

@ASTCT @BeTheMatch @AndrewRezvani @fmilano976 @DocBrunstein @NMDP @CIBMTR Patients with high-titer HLA antibodies/DSA, splenomegaly, myelofibrosis may also not be suitable for #cordblood transplantation.

Question 4: Are there patients for whom Cord Blood may not be a suitable stem cell source? #ASTCTChat @BeTheMatch @ipolitikos @AndrewRezvani @fmilano976 @DocBrunstein

@RahulBanerjeeMD @warren_fingrut @ASTCT @BeTheMatch @AndrewRezvani @fmilano976 @DocBrunstein @UCSFCancer @MSKCancerCenter Very important question. I believe this is one of the objectives of the ongoing @CIBMTR CTN 1702 (CTL-ALT-D). Maybe @NMDP has updated data on attrition rates for URDs? #bmtsm

@warren_fingrut @ASTCT @BeTheMatch @ipolitikos @AndrewRezvani @fmilano976 @DocBrunstein @UCSFCancer @MSKCancerCenter Agreed - a ton of this boils down to patient factors and even center factors (ease of typing, volume of cord bloods done annually). Does anyone know if NMDP or CIBMTR has looked at something similar nationally? I.e., “X% of pts got dCBT because no sib, URD, or haplo at all?”

Question 2: Is your center using Cord Blood as a stem cell source? Why or why not? #ASTCTChat @BeTheMatch @ipolitikos @AndrewRezvani @fmilano976 @DocBrunstein

@RahulBanerjeeMD @ASTCT @BeTheMatch @AndrewRezvani @fmilano976 @DocBrunstein @UCSFCancer Both stem cell sources very important for minority patients. Quality of available haplo donors and CB units also important in donor selection. Recent data from our center by @warren_fingrut : ashpublications.org/bloodadvances/…

@RahulBanerjeeMD @ASTCT @BeTheMatch @AndrewRezvani @fmilano976 @DocBrunstein @UCSFCancer Agree! Haplo donors also significantly extend HSCT access to patients w/o SIB/MUDs. Per CTN1101 & the Spanish MAC haplo vs cord trial data, ~ 10% of HSCT pts would not have a suitable haplo donor. At our center, ~5-10% of pts getting a CB search don't have a suitable CB graft

We can’t wait to kick off our July #ASTCTChat today! We would like to disclose no COI with parties involved in this month's article. Remember to tag @ASTCT and #ASTCTChat to participate! @BeTheMatch ow.ly/TPS050K4Tiq

@ASTCT @BeTheMatch @AndrewRezvani @fmilano976 @DocBrunstein The low risk of cGVHD likely explains the low long-term healthcare burden after #cordblood transplantation. Very nice paper by @sghmd @DocBrunstein ans UMN colleagues: ashpublications.org/bloodadvances/…

@ASTCT @BeTheMatch @AndrewRezvani @fmilano976 @DocBrunstein Advantages of #cordblood include: 1) rapid graft availability - beneficial in urgent HSCT patients. 2) less stringent HLA-matching - important for extending transplant access to patients of non-europea or mixed ancestry. 3) low relapse rates. 4) low rates of cGVHD.

Question 1: What are the advantages of Cord Blood as a stem cell source? #ASTCTChat @BeTheMatch @ipolitikos @AndrewRezvani @fmilano976 @DocBrunstein

Today’s #ASTCTChat will discuss Guidelines for #CordBlood #Transplant. Authors include @ipolitikos, Karen Ballen, @AndrewRezvani, @fmilano976, Juliet Barker, @DocBrunstein and Leland Metheny. @BeTheMatch @ELShematology astctjournal.org/article/S2666-…

Extended Duration Letermovir Prophylaxis for Cytomegalovirus Infection after Cord Blood Transplantation in Adults ashpublications.org/bloodadvances/… @MSKCancerCenter @MSK_DeptOfMed @ipolitikos @DrMiguelPerales @GunjanLShah @GenPapaMD @sean_m_devlin Extend letermovir in all high risk patient